What is the Org number of Tibi Pharma AB?

Tibi Pharma AB is registered with Bolagsverket / SCB under Org 5594537648.

What is the revenue of Tibi Pharma AB?

Tibi Pharma AB reported revenue of SEK 1,6M in 2025.

Who is the CEO of Tibi Pharma AB?

Shan Rehman is Chief Executive Officer of Tibi Pharma AB, in role since 2023.

Who is the chairman of Tibi Pharma AB?

Helena Maria Westermark chairs the board of Tibi Pharma AB, in role since 2023.

Where is Tibi Pharma AB headquartered?

Tibi Pharma AB's registered address is Danderydsvägen 146.

Tibi Pharma AB

ABActive

Org 5594537648Danderydsvägen 146Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20230 employees

Full Risika report

Revenue 2025

SEK 1,6M

+151% vs 2024

EBITDA margin

2.4%

+147% vs 2024

Equity ratio

64.1%

Financial strength

Net profit 2025

SEK 39K

+147% vs 2024

EBITDA — year on yearSEK millions

Key figuresAnnual report 2025

Revenue	SEK 1,6M	+151%
EBITDA	SEK 39K	+147%
Net profit	SEK 39K	+147%
Total assets	SEK 868K	+256%
Equity	SEK 556K	+156%
Employees	0	—

Item	2024	2025
Revenue	637	1 598
Staff expenses	—	—
EBITDA	−83	39
Depreciation & amort.	−0	−0
EBIT	−83	39
Net financials	—	—
Profit before tax	−83	39
Tax	−0	−0
Net profit	−83	39

Item	2024	2025
Total assets	244	868
Equity	217	556
Long-term debt	0	0
Short-term debt	27	311
Total debt	27	311

Name	Role	Member since	Age	Other directorships
SR Shan Rehman Chief Executive Officer	Chief Executive Officer	2023	—	—
AM Anna Maria Andersson Audit	Audit	2023	—	—

Name	Role	Member since	Age	Other directorships
HM Helena Maria Westermark	Board of Directors	2023	—	—

Person	Role here	Other companies
Shan Rehman	Chief Executive Officer	0 companies
Anna Maria Andersson	Audit	0 companies
Helena Maria Westermark	Board of Directors	0 companies

Tibi Pharma AB

ABActive

Org 5594537648Danderydsvägen 146Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20230 employees

Full Risika report

Revenue 2025

SEK 1,6M

+151% vs 2024

EBITDA margin

2.4%

+147% vs 2024

Equity ratio

64.1%

Financial strength

Net profit 2025

SEK 39K

+147% vs 2024

EBITDA — year on yearSEK millions

Key figuresAnnual report 2025

Revenue	SEK 1,6M	+151%
EBITDA	SEK 39K	+147%
Net profit	SEK 39K	+147%
Total assets	SEK 868K	+256%
Equity	SEK 556K	+156%
Employees	0	—